primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
  1. Broan AM, Garcger CP, Sirbat D, et al. Comparison of two fixed beta-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group. Eur J Ophthalmol. 1997;7(4):351-356. Accessed 10 Feb 2012. PMID: 9457458
  2. Demailly P, Allaire C, Bron V, Trinquand C. Effectiveness and tolerance of beta blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. J Glaucoma. 1995 Aug;4(4):235-241. Accessed 10 Feb 2012. PMID: 19920680
  3. South East Asia Interest Group. Asia Pacific glaucoma guidelines. 2nd ed. Sydney, Australia: SEAGIG; 2008
  4. Henderson P, Labbe T, Kass MA. Ocular hypertension. In: Yanoff M, Duker JS, Augsburger JJ, et al. Yanoff & Duker: Ophthalmology. 3rd ed. Maryland Heights, MO: Mosby, Inc; 2008
  5. National Collaborating Centre for Acute Care. Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. http://www.nice.org.uk/nicemedia/live/12145/43887/43887.pdf.April. Apr 2009. Accessed 03 Feb 2012
  6. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Guidelines. Primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology. http://one.aao.org/summary-benchmark-detail/primary-openangle-glaucoma-suspect-summary-benchma. Oct 2013
  7. American Optometric Association Original Consensus Panel on Care of the Patient with Open-Angle Glaucoma. Optometric clinical practice guideline care of the patient with open-angle glaucoma. American Optometric Association. http://www.aoa.org/documents/CPG-9.pdf. 2010. Accessed 03 Feb 2012
  8. International Council of Ophthalmology. Primary open-angle glaucoma: initial evaluation. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoaglaucomainev_2.pdf. 2010. Accessed 04 Feb 2012
  9. International Council of Ophthalmology. Primary open-angle glaucoma: follow-up evaluation. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoaglaucomafu_2.pdf. 2010. Accessed 04 Feb 2012
  10. International Council of Ophthalmology. Primary open-angle glaucoma suspect: initial evaluation and follow-up. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoagsuspect_2.pdf. 2010. Accessed 06 Feb 2012
  11. Jacobs DS. Open-angle glaucoma: epidemiology, clinical presentation, and diagnosis. UpToDate. http://www.uptodate.com/contents/open-angle-glaucoma-epidemiology-clinical-presentation-and-diagnosis. 15 Jun 2015.
  12. Jacobs DS. Open-angle glaucoma: treatment. UpToDate. http://www.uptodate.com/contents/open-angle-glaucoma-treatment. 07 Apr 2015.
  13. European Glaucoma Society (EGS). Terminology and guidelines for glaucoma. 4th ed. EGS. http://www.eugs.org/eng/EGS_guidelines4.asp. Jun 2014.
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
17 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.